Ivabradina Teva Group (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous firing of the node, reducing heart rate without affecting contractility, which lessens myocardial oxygen demand.

The exact dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical status, heart‑rate response, and tolerance. Ivabradina Teva Group is supplied as a prescription‑only oral tablet, and dosing should follow the prescriber’s instructions.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Ivabradine selectively inhibits the If current without affecting blood pressure or contractility, whereas beta‑blockers block adrenergic receptors and can also reduce blood pressure. Ivabradine may be chosen when beta‑blockers are contraindicated or not tolerated.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed, unless the prescribing information specifically allows it.

Serious risks include severe bradycardia, atrioventricular block, syncope, and worsening heart failure. Patients should be monitored for symptoms such as dizziness, fainting, or palpitations, and the drug should be discontinued if heart rate falls below the safe threshold.

Ivabradina Teva Group is contraindicated in patients with sick‑sinus syndrome, second‑ or third‑degree atrioventricular block, severe hepatic impairment, or those who are already on strong CYP3A4 inhibitors without appropriate dose adjustment. It should also be avoided in individuals with known hypersensitivity to ivabradine.